Denali Therapeutics Inc.
DNLI
Updated: 24/09/2026, 19:47:23
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
No summaries found.
- Share price
- $20.08
- Market cap
- $3.19B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Ryan J. Watts
- Employees
- 503
- IPO date
- 08/12/2017
- Beta
- 1.005
- Last dividend
- $0.00
- Day range
- $19.73 – $20.43
- 52-week range
- $13.14 – $27.30
- 1-day performance
- -1.88%
- 1-year performance
- 52.78%
- Current drawdown (1Y)
- -26.47%
- CIK
- 0001714899
- CUSIP
- 24823R105
- ISIN
- US24823R1059
- Created
- 07/12/2025, 03:38:05
- Last update
- 24/09/2026, 19:47:23
Track Denali Therapeutics Inc. with an AI analyst
See which prediction-market events move DNLI, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 05/06/2026, 19:32:54
Denali Therapeutics (NASDAQ: DNLI) Stock Analysis: Navigating Setbacks and Seizing Growth Opportunities
Market Data • Market Data • 22/05/2026, 23:14:26
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
MarketBeat • STOCK • 16/05/2026, 08:08:49
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 00:00:48
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Zacks Investment Research • STOCK • 08/05/2026, 15:41:31
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
GlobeNewsWire • STOCK • 07/05/2026, 18:01:00
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Seeking Alpha • STOCK • 03/05/2026, 02:13:00
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Zacks Investment Research • STOCK • 17/04/2026, 16:40:25
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Zacks Investment Research • STOCK • 07/04/2026, 17:31:13
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Benzinga • STOCK • 06/04/2026, 15:26:27
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
Zacks Investment Research • STOCK • 26/03/2026, 16:26:06
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
GlobeNewsWire • STOCK • 25/03/2026, 12:50:00